$BioNTech (BNTX.US)$ From a comprehensive perspective, BNTX ...

$BioNTech (BNTX.US)$ From a comprehensive perspective, BNTX will become the best-performing vaccine stock! With the European preference and the approval of children’s vaccines, sales will continue to remain high. If the injections are strengthened every year, the current valuation level can be maintained. BNTX has not won other approvals yet, and BNTX has made money in Japan. Although it is not as expensive as mRNA and has a slightly lower profit, its cooperation with PFE has high yields and seizes opportunities from vaccines of all ages, almost always the first. Get approval. The performance should be very good, and the subsequent sales are endless. Especially in developed countries, they are also mRNA vaccines, and they will occupy a larger market if they are cheap.